November marks Lung Cancer Awareness Month and Precision Medicine Awareness Month. This year FT3 is pleased to share the first adaptable toolkit designed for champions of precision medicine that is now being piloted in lung cancer and beyond. This toolkit, which can be easily adapted to different countries and contexts, brings together and builds on existing good practices in the precision medicine (PM) community, and therefore not only addresses immediate barriers to access such as patient education and awareness, but also helps facilitate the need for greater collaboration and alignment within the PM community.

We are developing solutions in three distinct topic areas (data & evidence development, education & awareness, and addressing systemic barriers to access), as part of a broader strategy to enable greater access to precision medicine at the health system level, at the health care delivery level, and to support greater collaboration and alignment of the PM community. Throughout our work there is a deep focus on engaging patients as we endeavor to truly understand and improve the patient experience and their quality of life.

Quotes:
We all need to work together to improve precision medicine outcomes for patients. We call all stakeholders to join the FT3 Community of Practice to help us provide easy and equitable access for all patients who could benefit from precision medicine - Helena Harnik, Executive Director, FT3.

"Multi-stakeholder collaboration is the future of all developments in (Lung) Cancer. For those of us with a rare oncogene driven cancer, researchers are already getting to know each other's work and are willing to collaborate. I am involved in FT3 because I believe FT3's multi stakeholder approach is the best and most sustainable way to solve complex issues in precision medicine access" - Merel Hennink, Founder, Stichting Merels Wereld

"Multi-stakeholder collaborations provide the opportunity to harness resources and pool knowledge. In this way we will create impactful change for patients in the most efficient and timely way possible” - Andrea Ferris, President and CEO of LUNGevity Foundation

"Lung cancer is a complex heterogeneous disease, therefore it is crucial that people know as much about their tumor type as possible, as this will help to identify the best possible care. There is so much information out there that it can be difficult to wade through it and find accurate quality information. We believe that being part of the FT3 community will make it easier to map what already exists, identify gaps, and design solutions to fill those gaps” - Dr Anne Marie Baird, President of Lung Cancer Europe and molecular biologist
About FT3:
The From Testing to Targeted Treatments (FT3) program is a global, not-for-profit, multi-stakeholder collaborative program to make precision medicine an accessible reality for patients who could benefit. Our aim is to act as a global accelerator in PM, identifying global learnings and good practices and turning them into practical tools and solutions to advance patient access to PM that are adaptable at the local level.

Main contact point: Lise Brooke, lise@thesynergist.org